RJA
DMK

Raymond James & Associates’s DMK Pharmaceuticals Corporation Common Stock DMK Stock Holding History

Raymond James & Associates’s Portfolio DMK Stock Details DMK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-232
Closed -$16K – 4313
2021
Q3 		$16K Buy
232
+66
+40% +$4.83K ﹤0.01% 4023
2021
Q2 		$13K Buy
+166
New +$10.1K ﹤0.01% 4019
2019
Q4 		– Sell
-916
Closed -$45K – 3771
2019
Q3 		$45K Buy
916
+235
+35% +$16.9K ﹤0.01% 3480
2019
Q2 		$62K Buy
681
+22
+3% +$2.68K ﹤0.01% 3478
2019
Q1 		$97K Sell
659
-50
-7% -$9.67K ﹤0.01% 3393
2018
Q4 		$112K Buy
709
+256
+57% +$49.1K ﹤0.01% 3288
2018
Q3 		$111K Buy
+453
New +$107K ﹤0.01% 3421
2018
Q1 		– Sell
-154
Closed -$47K – 3616
2017
Q4 		$47K Sell
154
-76
-33% -$25K ﹤0.01% 3286
2017
Q3 		$84K Buy
230
+76
+49% +$27K ﹤0.01% 3198
2017
Q2 		$56K Sell
154
-2,445
-94% -$732K ﹤0.01% 3175
2017
Q1 		$773K Buy
2,599
+158
+6% +$39.9K ﹤0.01% 2121
2016
Q4 		$538K Buy
2,441
+889
+57% +$178K ﹤0.01% 2292
2016
Q3 		$373K Buy
+1,552
New +$323K ﹤0.01% 2477
2016
Q2 		– Sell
-586
Closed -$252K – 3105
2016
Q1 		$252K Sell
586
-196
-25% -$70K ﹤0.01% 2449
2015
Q4 		$296K Buy
+782
New +$245K ﹤0.01% 2197
2015
Q2 		– Sell
-740
Closed -$204K – 2458
2015
Q1 		$204K Buy
+740
New +$320K ﹤0.01% 2321

Other funds holding DMK

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Raymond James & Associates's DMK Position: Q4 2021 in Review

Raymond James & Associates sold out of DMK Pharmaceuticals Corporation Common Stock (DMK) in Q4 2021, closing a stake of 232 shares — an estimated $16K sold.

Raymond James & Associates first reported a position in DMK in Q1 2015 and held it in 16 quarters. The position peaked at $773K in Q1 2017. 49 funds tracked by Wall St. Rank hold DMK as of Q4 2021.

  • Raymond James & Associates reported no remaining DMK Pharmaceuticals Corporation Common Stock position as of Q4 2021 after selling out during the quarter.
  • Raymond James & Associates sold 232 DMK Pharmaceuticals Corporation Common Stock shares in Q4 2021, an estimated $16K.
  • Raymond James & Associates first reported a position in DMK Pharmaceuticals Corporation Common Stock in Q1 2015 and held it in 16 quarters.
  • Raymond James & Associates's DMK Pharmaceuticals Corporation Common Stock position peaked at $773K in Q1 2017.
  • 49 funds tracked by Wall St. Rank held DMK Pharmaceuticals Corporation Common Stock as of Q4 2021.

Based on Raymond James & Associates's 13F filing for Q4 2021, filed 8 Feb 2022.